CP
PTLA

Corbenic Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Corbenic Partners’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-30
Closed – – 204
2020
Q1 		$0 Sell
30
-83
-73% -$1.04K ﹤0.01% 224
2019
Q4 		$3K Buy
+113
New +$3.12K ﹤0.01% 153

Other funds holding PTLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Corbenic Partners's PTLA Position: Q2 2020 in Review

Corbenic Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 30 shares.

Corbenic Partners first reported a position in PTLA in Q4 2019 and held it in 2 quarters. The position peaked at $3K in Q4 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

  • Corbenic Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Corbenic Partners sold 30 Portola Pharmaceuticals, Inc. shares in Q2 2020.
  • Corbenic Partners first reported a position in Portola Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • Corbenic Partners's Portola Pharmaceuticals, Inc. position peaked at $3K in Q4 2019.
  • 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Corbenic Partners's 13F filing for Q2 2020, filed 17 Jul 2020.